Whalesbook
Soch rahe hoge yeh buyback hai kya cheez? Simple language mein, company apne khud ke shares market se wapas kharid rahi hai. Aurobindo Pharma plan kar raha hai ki woh tender offer ke through 54.23 lakh shares khareede, jiske liye ₹800 crore lagane wale hain. Har share ka rate hoga ₹1,475. Yeh offer April 23 se April 29, 2026 tak open rahega, aur jin shareholders ka naam April 17, 2026 tak register hoga, woh ismein apply kar sakte hain.
Sabse mast baat ye hai ki yeh ₹1,475 ka offer price current market price ₹1,387.05 (April 21, 2026 tak) se kaafi upar hai. Matlab, agar tumhare paas shares hain, toh tum unhe is offer price par bech kar achha premium kama sakte ho. Stock ne khud bhi recent time mein ₹1,401 ka 52-week high banaya tha aur Sensex se bhi achha perform kiya hai.
Company ne pehle bhi August 2024 mein ₹750 crore ka buyback ₹1,460 per share par kiya tha. Is baar bhi buyback karna management ka confidence dikhata hai ki stock abhi undervalued hai.
Abhi Indian pharma market ki baat karte hain. US mein toh problems chal rahi hain, but India mein toh market zabardast grow kar raha hai. March 2026 tak ke fiscal mein toh India ka pharma market kaafi grow kiya hai.
Aurobindo Pharma ka P/E ratio lagbhag 22.8x hai, jo industry ke 28x average se kam hai. Comparison mein Cipla aur Lupin bhi isi range mein hain, jabki Natco Pharma aur Zydus Lifesciences thode cheap mil rahe hain. Valuation ke hisaab se Aurobindo Pharma filhaal attractive lag raha hai, especially India mein jo strength dikha raha hai.
Analysts bhi is par bullish hain aur generally 'Buy' rating de rahe hain. Unka average target ₹1,380 ke aas paas hai.
Par sab kuch itna bhi smooth nahi hai. US business mein growth slow hai aur prices par pressure hai. Buyback ka size bhi company ki total equity ka sirf 0.93% hai, jo bahut bada nahi hai. Plus, company ko international regulations aur nayi markets mein bhi challenges face karne padenge. Aur PEG ratio 2.36 thoda high lag raha hai, jo growth ke comparison mein overvaluation ka issue dikha sakta hai.
Lekin, kuch firms ne kaafi high targets bhi diye hain, jaise JM Financial ka ₹1,610 aur HDFC Securities ka ₹1,755. Agar company apna domestic business badhati hai aur capital ko smartly manage karti hai, toh future mein achha perform kar sakti hai aur healthcare ki badhti demand ka fayda utha sakti hai.